UY27253A1 - USE OF THE BIBH1 SPECIFIC ANTIBODY OF THE FIBROBLAST ACTIVATION PROTEIN (FAP) IN THE TREATMENT OF CANCER - Google Patents

USE OF THE BIBH1 SPECIFIC ANTIBODY OF THE FIBROBLAST ACTIVATION PROTEIN (FAP) IN THE TREATMENT OF CANCER

Info

Publication number
UY27253A1
UY27253A1 UY27253A UY27253A UY27253A1 UY 27253 A1 UY27253 A1 UY 27253A1 UY 27253 A UY27253 A UY 27253A UY 27253 A UY27253 A UY 27253A UY 27253 A1 UY27253 A1 UY 27253A1
Authority
UY
Uruguay
Prior art keywords
bibh1
cancer
fap
treatment
specific antibody
Prior art date
Application number
UY27253A
Other languages
Spanish (es)
Inventor
Andree Amelsberg
Andrew Scott
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Int
Priority to UY27253A priority Critical patent/UY27253A1/en
Publication of UY27253A1 publication Critical patent/UY27253A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

La invención incluye el uso terapéutico de un anticuerpo humanizado que se une específicamente 4 a la molécula conocida como FAPa. El anticuerpo, conocido como BIBH1 tiene una semivida muy corta y cuando está marcado con un marcador terapéutico, es eficaz para tratar tumores malignos tales como el cáncer colorrectal y el cáncer de pulmón de células no pequenas. Se describen diferentes modos de usar el anticuerpo.The invention includes the therapeutic use of a humanized antibody that specifically binds 4 to the molecule known as FAPa. The antibody, known as BIBH1 has a very short half-life and when labeled with a therapeutic marker, it is effective in treating malignant tumors such as colorectal cancer and non-small cell lung cancer. Different ways of using the antibody are described.

UY27253A 2002-04-10 2002-04-10 USE OF THE BIBH1 SPECIFIC ANTIBODY OF THE FIBROBLAST ACTIVATION PROTEIN (FAP) IN THE TREATMENT OF CANCER UY27253A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY27253A UY27253A1 (en) 2002-04-10 2002-04-10 USE OF THE BIBH1 SPECIFIC ANTIBODY OF THE FIBROBLAST ACTIVATION PROTEIN (FAP) IN THE TREATMENT OF CANCER

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UY27253A UY27253A1 (en) 2002-04-10 2002-04-10 USE OF THE BIBH1 SPECIFIC ANTIBODY OF THE FIBROBLAST ACTIVATION PROTEIN (FAP) IN THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
UY27253A1 true UY27253A1 (en) 2002-11-29

Family

ID=38812622

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27253A UY27253A1 (en) 2002-04-10 2002-04-10 USE OF THE BIBH1 SPECIFIC ANTIBODY OF THE FIBROBLAST ACTIVATION PROTEIN (FAP) IN THE TREATMENT OF CANCER

Country Status (1)

Country Link
UY (1) UY27253A1 (en)

Similar Documents

Publication Publication Date Title
AR033157A1 (en) USE OF PROTEIN ALFA OF ACTIVATION OF FIBROBLASTS ("FAPAALFA") BIBH1 IN THE TREATMENT OF CANCER
CY1117031T1 (en) CLAUDIN-18 Monoclonal Antibodies In Cancer Treatment
AR033978A1 (en) ANTIBODY MOLECULA WITH SPECIFICITY FOR HUMAN ALPHA TUMOR NECROSIS FACTOR AND USES OF THE SAME
CL2007001624A1 (en) Use of an antibody that binds to dll4 for the treatment of tumor, cancer or cell proliferation disorder.
CY1109525T1 (en) HUMANIZED ANTI-ErbB2 ANTIBODIES AND THERAPEUTIC TREATMENT WITH ANTI-ErbB2 ANTIBODIES
ES2181006T3 (en) USE OF AMIDAS OF PIRIDIL ALCANOS ACIDS, PIRIDIL ALKENS AND / OR PIRIDIL ALKINES IN THE TUMOR TREATMENT OR IN IMMUNOSUPPRESSION.
ES2141128T3 (en) COMBINATION OF ANTI-HORMONAL AGENTS AND FIXING MOLECULES.
BR0315666A (en) A34 and a33 type 3 dna, proteins, their antibodies and treatment methods using the same
ECSP099523A (en) VEGF specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
TR200202183T2 (en) Peptidase cleavable targeted antineoplastic drugs and their therapeutic uses
BRPI0207961A8 (en) USE OF EPOTHYLONE AND CAPECITABIN ANALOGS TO MANUFACTURE DRUG TO TREAT SOLID CANCEROUS TUMORS AND KIT COMPRISING THE SAID COMPOUNDS.
EA200801853A1 (en) EFFECTIVE PEPTIDES IN THE TREATMENT OF TUMORS AND OTHER DISEASES THAT REQUIRE REMOVAL OR DESTRUCTION OF CELLS
ATE486087T1 (en) FGF-5 BINDING AND SUPPORTED PEPTIDES
AR086510A2 (en) UNION AGENTS SPECIFIC TO THE GROWTH FACTOR OF HEPATOCITS
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
BRPI0509177A (en) use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
EA200200616A1 (en) CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENT
ATE502025T1 (en) ARYLCARBOXAMIDES AND THEIR USE AS ANTI-TUMOR AGENTS
ECSP10010729A (en) PEPTIDES DIRECTED TO CRKL
AR121691A1 (en) CLAUDIN-TARGETED RNA COMPOSITIONS-18.2
EA200970884A1 (en) METHODS OF TREATING CANCER BY INTRODUCING HUMAN INTERLEUKIN IL-18 COMBINATIONS
EE200300467A (en) Targeting liposomes by matrix metalloproteinase inhibitors
DE60129741D1 (en) TARGETED COMBINATION IMMUNOTHERAPY FOR CANCER AND INFECTION DISEASES
UY27253A1 (en) USE OF THE BIBH1 SPECIFIC ANTIBODY OF THE FIBROBLAST ACTIVATION PROTEIN (FAP) IN THE TREATMENT OF CANCER
ECSP045408A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES ARSENITE FOR THE TREATMENT OF MALIGNITY

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160201